Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
13 December, 2018 05:18 IST
Infosys announces intent to voluntarily delist ADS
Source: IRIS | 13 Mar, 2018, 08.54AM
Comments  |  Post Comment

Infosys announced its intention to voluntarily delist its American Depositary Shares (ADS) (ISIN US4567881085) from the Euronext Paris and Euronext London exchanges. The primary reason for seeking the proposed delisting is the low average daily trading volume of Infosys ADS on these exchanges, which is not commensurate with the related administrative requirements. During the 5-year period of the company's listing on Euronext Paris and Euronext London, the average daily trading volume of the company's ADS was significantly lower than its average daily trading volume on the New York Stock Exchange (NYSE).

The proposed delisting is subject to approval from Euronext Paris S.A. and Euronext London Limited. There will be no change to the Infosys share/ADS count, capital structure and float, as a result of the proposed delisting from the above exchanges. Infosys ADS will continue to be listed on the NYSE under the symbol "INFY" and investors can continue to trade their ADS on the NYSE as before.

Shares of the company gained Rs 22.45, or 1.93%, to trade at  Rs 1,185.85.  The total volume of shares traded  was  373,881 at the BSE (4.01 p.m., Monday).



Infosys Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
Ashok Leyland signs defence agreement with ELBIT Systems - 12-Dec-2018 09:41
Wipro launches automotive innovation center in Michigan - 12-Dec-2018 09:37
Liva Pharmaceuticals gets USFDA approval for its sANDA - Ranitidine Injection - 12-Dec-2018 09:35
Dr Reddy's Labs launches Omeprazole tablets in US market - 12-Dec-2018 09:31
Strides Vivimed JV receives consent for Albendazole tablets - 12-Dec-2018 09:27
Unichem Lab gets tentative nod for Tadalafil tablets - 12-Dec-2018 09:25
Zydus Wellness gets CCI approval for acquisition of Heinz India - 12-Dec-2018 09:20
Wipro Digital to expand Asia Pacific design capabilities in Australia - 11-Dec-2018 09:26
Wipro Digital to expand Asia Pacific design capabilities in Australia - 11-Dec-2018 09:24
Lupin receives tentative USFDA approval for Apixaban tablets - 11-Dec-2018 09:20
Lupin receives EIR from USFDA for Indore facility - 10-Dec-2018 16:10
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer